发表论文

分类：药品研发
发布时间：2021-06-01 10:33:18
访问量：0

概要:

详情

重组人肝细胞生长因子裸质粒治疗慢性缺血性疾病的系统评价与Meta分析

Recombinant Human Hepatocyte Growth Factor Plasmids for Treating Patients with Chronic Limb Threatening Ischaemia: A Systematic Review and Meta-analysis

European Journalof Vascular&EndovascularSurgery (2024)

http://doi.org/10.1016/j.ejvs.2024.07.016.

NL003II期临床试验长期随访结果论文

Nine-year follow-up of patients receiving recombinant human hepatocyte growth factor nude plasmid DNA for critical limb ischemia: Updated safety and efficacy results

Vascular Investigation and Therapy（ISSN:2589-9686) DOI:10.4103/vit_21_24

NL003 III期临床试验方案论文

Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): Randomized, placebo-controlled, double-blind, phase III clinical trials

American heart journal, vol. 2022 Aug 21;254:88-101.

NL003 II期临床试验论文

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia

Molecular Therapy. 2019 Dec 4;27(12):2158-2165.

NL003 I期临床试验论文

A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia.

The Journal of Gene Medicine. 2011 Nov;13(11):602-10.

NL005 I期临床试验论文

A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers

Journal of Cellular and Molecular Medicine. 2021 Aug 4.doi: 10.1111/jcmm.16693.

扫二维码用手机看